3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
9
Rhabdomyosarcoma
7
Wilms Tumor
6
Malignant mesenchymal tumor
6
Ovarian Neoplasms
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Melanoma
2
Liposarcoma
2
Kidney Neoplasms
2
Hydatidiform Mole
2
Hemangiosarcoma
2
Hemangiopericytoma, Malignant
2
Fibrosarcoma
2
Desmoplastic Small Round Cell Tumor
2
Testicular Neoplasms
1
Teratoma, Ovarian
1
Sarcoma, Ewing
1
Rhabdoid Tumor
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Germ Cell and Embryonal
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Gestational Trophoblastic Disease
1
Choriocarcinoma
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Blast Crisis
1
Beckwith-Wiedemann Syndrome
1
Interventions
Cyclophosphamide
10
Irinotecan
8
Melphalan
7
Vincristine
6
Temozolomide
6
Doxorubicin
6
Busulfan
6
Topotecan
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Ifosfamide
4
Filgrastim
4
Etoposide
4
Albumin-Bound Paclitaxel
4
Trabectedin
3
Sirolimus
3
Nivolumab
3
130-nm albumin-bound paclitaxel
3
pegfilgrastim
2
olaparib
2
fludarabine phosphate
2
fludarabine
2
eribulin
2
cixutumumab
2
abemaciclib
2
X-Rays
2
Radiotherapy, Intensity-Modulated
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Sarcoma, Ewing
×
Dactinomycin
×
Clear all
NCT02063022
2022-09-19
EW-1
Italian Sarcoma Group
Phase 3
Completed
278 enrolled